{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=17",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:59:14.694Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01385215",
      "title": "Strategies for Enhancing Mucosal Immunity to Influenza Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Mucosal Immunity"
      ],
      "interventions": [
        {
          "name": "Fluzone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Sundy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-04",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-12-06",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385215"
    },
    {
      "nct_id": "NCT04537208",
      "title": "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "CoV2 preS dTM-AF03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AF03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM (high-dose) without adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 441,
      "start_date": "2020-09-03",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04537208"
    },
    {
      "nct_id": "NCT03480763",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PNEUMOVAX™23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 652,
      "start_date": "2018-06-22",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 15,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480763"
    },
    {
      "nct_id": "NCT00974935",
      "title": "Phase I STEBVax in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Toxic Shock Syndrome Staphylococcal"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "STEBVax vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 29,
      "start_date": "2011-02",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-06-19",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974935"
    },
    {
      "nct_id": "NCT00905125",
      "title": "Influenza Vaccine in Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 102,
      "start_date": "2009-06",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2012-06-13",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 9,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00905125"
    },
    {
      "nct_id": "NCT03303625",
      "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Ad26.RSV.preF (1*10^11 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.RSV.preF (5*10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-11-29",
      "completion_date": "2020-04-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 1,
      "location_summary": "Newton, Kansas",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303625"
    },
    {
      "nct_id": "NCT05477186",
      "title": "Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV0501 (3 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (6 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (12 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (25 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (50 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (100 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (200 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2022-08-12",
      "completion_date": "2023-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477186"
    },
    {
      "nct_id": "NCT06069544",
      "title": "A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "BNT165c",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT165d",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 163,
      "start_date": "2023-11-13",
      "completion_date": "2026-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 5,
      "location_summary": "Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06069544"
    },
    {
      "nct_id": "NCT07086222",
      "title": "Efficacy and Safety of NVX-CoV2705",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19",
        "Sars-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "NVX-CoV2705",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "50 Years to 65 Years"
      },
      "enrollment_count": 6500,
      "start_date": "2025-11-20",
      "completion_date": "2026-10-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 99,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07086222"
    },
    {
      "nct_id": "NCT02543918",
      "title": "A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        },
        {
          "name": "Boostrix®",
          "type": "DRUG"
        },
        {
          "name": "Pneumovax®23",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-09",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-11-15T18:59:14.694Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543918"
    }
  ]
}